
NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (NuTide:302)

Background

- CRC 3rd most common cancer
 Incidence: 1.9 million¹
 Annual deaths: 935,000¹
- 5-FU remains the cornerstone of treatment for CRC, despite several limitations
- Rapidly degraded by DPD²
- Short plasma half-life (8-14 mins)³ necessitates prolonged (46-hour) infusions Generation of FBAL (associated with hand-foot syndrome)
- Generation of FUTP (associated with dose-limiting RNA toxicities; diarrhea, mucositis, myelosuppression)
- Cell entry requires nucleoside transporters
- Complex enzymatic activation


NUC-3373 overcomes key limitations associated with 5-FU



NUC-3373: A targeted inhibitor of TS

DNA DAMAGE

- ProTide transformation of FUDR-MP^{4,5}, the active anti-cancer metabolite of 5-FU Resistant to breakdown by DPD
- Able to enter cells independently of nucleoside transporters
- Low levels of toxic catabolites (FBAL, FUTP)
- Generates high levels of FUDR-MP⁶, which binds to TS
- Causes an imbalance in the nucleotide pool leading to DNA damage and cell death⁷
- Induces ER stress and DAMP release leading to immunogenic cell death^{8,9}



NUFOX NUFOX NUFOX NUFOX NUFOX NUFOX NUFOX NUFOX NUFOX NUFOX

Baseline Ch	aracteristics	(n=23)
Age, years	Median (range)	61 (40-75)
Gender	Male Female	11 (48%) 12 (52%)
ECOG PS	0 1	12 (52%) 11 (48%)
Metastatic Sites, n	1-3 ≥4	14 (61%) 9 (39%)
RECIST Target Lesions	Liver Lung Abdomen Lymph nodes Other	 13 (57%) 13 (57%) 7 (30%) 5 (22%) 7 (30%)
KRAS Mutated*	Yes No	16 (70%) 6 (26%)
Prior Lines	Median (range)	3 (2-8)
Prior Lines, n	2 3 4 5+	 7 (30%) 8 (35%) 3 (13%) 5 (22%)
Prior Bev Exposure 1 pt KRAS status unkr	Yes No	11 (48%) 12 (52%)


Safety Profile								
NUC-3373 / oxaliplatin Dose (mg/m²)	1500 / 85 n=4		1875 / 85 n=10 MTD		2250 / 85 n=9		Total n=23	
	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3
Nausea	3 (75%)	0	5 (50%)	1 (10%)	5 (56%)	1 (11%)	13 (57%)	2 (9%)
Diarrhea	2 (50%)	0	4 (40%)	0	4 (44%)	0	10 (43%)	0
Vomiting	2 (50%)	0	4 (40%)	1 (10%)	4 (44%)	0	10 (43%)	1 (4%)
Stomatitis	0	0	1 (10%)	0	2 (22%)	0	3 (13%)	0
ALT increased	2 (50%)	2 (50%)	1 (10%)	0	2 (22%)	1 (11%)	5 (22%)	3 (13%)
AST increased	1 (25%)	0	2 (20%)	0	2 (22%)	0	5 (22%)	0
Appetite decreased	1 (25%)	0	3 (30%)	0	3 (33%)	0	7 (30%)	0
Hypokalemia	0	0	1 (10%)	1 (10%)	1 (11%)	0	2 (9%)	1 (4%)
Hyperuricemia	0	0	0	0	1 (11%)	1 (11%)	1 (4%)	1 (4%)
Anemia	0	0	1 (10%)	0	5 (56%)	0	6 (26%)	0
Thrombocytopenia	0	0	1 (10%)	1 (10%)	1 (11%)	0	2 (9%)	1 (4%)
Fatigue	3 (75%)	0	5 (50%)	0	5 (56%)	2 (22%)	13 (57%)	2 (9%)
Infusion-related reaction	1 (25%)	0	2 (20%)	0	1 (11%)	0	4 (17%)	0
Headache	1 (25%)	0	0	0	2 (22%)	0	3 (13%)	0
Feeling hot	2 (50%)	0	0	0	1 (11%)	0	3 (13%)	0
Chills	0	0	0	0	3 (33%)	1 (11%)	3 (13%)	1 (4%)
Pyrexia	0	0	0	0	1 (11%)	1 (11%)	1 (4%)	1 (4%)
Infection	0	0	0	0	1 (11%)	1 (11%)	1 (4%)	1 (4%)
21 out of 23 patients experienced a TRAE TRAEs reported are related to NUC-3373 or NUC-3373 & oxaliplatin; All grade TRAEs with incidence of ≥10% in any dose cohort; All grade 3 TRAEs reported								

All patients had received prior 5-FU, oxaliplatin & irinotecal

No Grade 4 or 5 TRAEs


Discontinuation rate due to adverse events was low (13%)


MTD: NUC-3373 1875 mg/m² + LV 400 mg/m² + oxaliplatin 85 mg/m²





- DLTs in 3 patients





- FOLFOX¹⁰ & FOLFIRI¹¹ historical data
- RP2D for NUC-3373

- NUFOX: NUC-3373 1875 mg/m² + LV 400 mg/m² + oxaliplatin 85 mg/m² • NUFIRI: NUC-3373 1500 mg/m² + LV 400 mg/m² + irinotecan 180 mg/m²
- NUC-3373 PK profile unchanged by oxaliplatin or irinotecan NUC-3373 has a convenient dosing schedule

-) Duke University Medical Center, Durham, NC, U 8) NuCana plc, Edinburgh, UK


 Grade 3 fatigue (2 pts at NUC-3373 2250 mg/m² + oxaliplatin 85 mg/m²) Grade 3 ALT increased / Grade 2 bilirubin increased (1 pt at NUC-3373 2250 mg/m² + oxaliplatin 85 mg/m²)

Baseline Characteristics (n=23)						
Age, years	Median (range)	56 (36-74)				
Gender	Male Female	8 (35%) 15 (65%)				
ECOG PS	0 1	12 (52%) 11 (48%)				
Metastatic Sites, n	1-3 ≥4	12 (52%) 11 (48%)				
RECIST Target Lesions	Liver Lung Abdomen Lymph nodes Other	17 (74%) 14 (61%) 5 (22%) 8 (35%) 9 (39%)				
KRAS Mutated*	Yes No	17 (74%) 5 (22%)				
Prior Lines	Median (range)	4 (2-10)				
Prior Lines, n	2 3 4 5+	5 (22%) 3 (13%) 6 (26%) 9 (39%)				
Prior Bev Exposure *1 pt KRAS status unkr All patients had receive	Yes No nown ed prior 5-FU, oxaliplatin	14 (61%) 9 (39%) & irinotecan				

Safety Profile										
NUC-3373 / irinotecan Dose (mg/m²)	1500 / 120 n=4		1500 / 150 n=4		1500 / 180 n=9 MTD		1875 / 180 n=6		Total n=23	
	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3
Nausea	2 (50%)	0	2 (50%)	1 (25%)	4 (44%)	0	2 (33%)	0	10 (43%)	1 (4%)
Diarrhea	3 (75%)	0	1 (25%)	0	1 (11%)	0	2 (33%)	1 (17%)	7 (30%)	2 (9%)
Vomiting	2 (50%)	0	0	0	2 (22%)	0	2 (33%)	0	6 (26%)	0
Colitis	0	0	1 (25%)	0	0	0	1 (17%)	1 (17%)	2 (9%)	1 (4%)
ALT increased	2 (50%)	0	1 (25%)	0	2 (22%)	2 (22%)	0	0	5 (22%)	2 (9%)
AST increased	2 (50%)	0	0	0	1 (11%)	0	0	0	3 (13%)	0
ALP increased	0	0	0	0	1 (11%)	1 (11%)	0	0	1 (4%)	1 (4%)
Appetite decreased	1 (25%)	0	0	0	2 (22%)	0	2 (33%)	0	5 (22%)	0
Hypomagnesemia	0	0	1 (25%)	0	2 (22%)	0	0	0	3 (13%)	0
Anemia	0	0	2 (50%)	0	2 (22%)	0	1 (17%)	0	5 (22%)	0
Fatigue	1 (25%)	0	1 (25%)	0	3 (33%)	1 (11%)	2 (33%)	1 (17%)	7 (30%)	2 (9%)
Proteinuria	0	0	1 (25%)	1 (25%)	0	0	0	0	1 (4%)	1 (4%)
18 out of 23 patients experienced a TRAE TRAEs reported are related to NUC-3373 or NUC-3373 & irinotecan; All grade TRAEs with incidence of ≥10% in any dose cohort; All grade 3 TRAEs reported										

No Grade 4 or 5 TRAEs

- Discontinuation rate due to adverse events was low (9%)
- MTD: NUC-3373 1500 mg/m² + LV 400 mg/m² + irinotecan 180 mg/m²



Conclusions & Future Plans

• NUFOX & NUFIRI have favorable safety profiles compared to

- Encouraging signs of anti-tumor activity in heavily pretreated patients who have received prior 5-FU, oxaliplatin and irinotecan
- Prolonged SD: NUFOX 6 patients >3 months; NUFIRI - 6 patients >3 months
- Future Plans
- Randomized Phase 2 Study (NuTide: 323) NUFIRI-bev vs FOLFIRI-bev in second-line CRC initiated

Andrew L Coveler¹, Aglaia Skolariki², Kristen K Ciombor³, Hélène Marijon⁴, Janet S Graham⁵, Mary Linton Peters⁶, Stacey A Cohen¹, Niharika B Mettu⁷, Michelle Myers⁸, Elisabeth Oelmann⁸, Jeffrey D Bloss⁸, Sarah P Blagden², Aimery de Gramont⁴, Jordan Berlin³, and TR Jeffry Evans⁵

FPN Number 354P

Email: acoveler@uw.edu




NUFIRI NUFIRI NUFIRI NUFIRI NUFIRI NUFIRI NUFIRI NUFIRI NUFIRI

DLTs in 3 patients

Grade 3 ALT/ALP increased (1 pt at NUC-3373 1500 mg/m² + irinotecan 180 mg/m²)

Grade 3 colitis (1 pt at NUC-3373 1875 mg/m² + irinotecan 180 mg/m²) Grade 3 fatigue (1 pt at NUC-3373 1875 mg/m² + irinotecan 180 mg/m²)



Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors

Data cleaning ongoing; data cut off <u>5 Aug 2022</u>